Core Insights - The company is entering an exciting phase with the Angelman Phase III trial, indicating significant progress in its development pipeline [1] - Founded in 2010 and went public in 2014, the company is led by CEO Emil Kakkis and focuses on rare diseases with high unmet medical needs [1] Company Overview - The company emphasizes a commitment to rare diseases, aiming to address areas where there is still a high level of unmet medical need [2] - It employs a diverse range of platforms, including enzyme replacement therapy and small molecule gene therapy, to tackle these diseases effectively [2]